Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vactosertib + Paclitaxel in Metastatic Gastric Cancer
NCT03698825Phase 2Completed
- Sponsor
- MedPacto
- Start
- Aug 2018
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vactosertib in gastric adenocarcinoma, sponsored by MedPacto. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Started Aug 2018; status: completed.
02
Drugs
vactosertib
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT03698825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03698825.